InsidersTradesSigma
Follow the Envista Holdings Corp stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Envista Holdings Corp has logged 175 insider filings. Market capitalisation: €4.4bn. The latest transaction was disclosed on 27 August 2026 (Retenue fiscale). Among the most active insiders: Reis Mischa. All data is openly available.
175
Insider Decl.
n/a
Thresholds
€1m
9 ops.
Buy Volume
€3m
15 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Envista Holdings Corp Buy (bullish), based on 14 analysts. Average price target: US$30.57.
26Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 18,383 of 29,062 companies
43.7
score / 100
Value46
Quality42
FCF yld5.3%
Earn yld1.1%
EV/EBITDA16.3x
ROE3.1%
Gross mgn55%
Net mgn1.7%
Debt/EBITDA4.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations175 total
7,710 shares@ US$27.47Common StockSEC:0002045846-26-000007:0
5,147 shares@ US$27.47Common StockSEC:0002012361-26-000007:0
10,885 shares@ US$27.47Common StockSEC:0001610493-26-000009:0
804 shares@ US$27.47Common StockSEC:0002045818-26-000005:0
8,000 shares@ US$27.50Common StockSEC:0001788632-26-000009:0
8,000 shares@ US$27.500.0051% mcap10.3% of flowCommonSEC144:0001959173-26-006259
179,730 shares0Common StockSEC:0001626337-26-000010:0
12,811 shares@ US$23.430.0068% mcap14.7% of flowCommon StockSEC:0001626337-26-000005:0
9,330 shares0Common StockSEC:0001563565-26-000003:0
9,330 shares0Common StockSEC:0001278861-26-000008:0
9,330 shares0Common StockSEC:0001306860-26-000003:0
9,330 shares0Common StockSEC:0001308428-26-000003:0
12,585 shares0Common StockSEC:0001365493-26-000003:0
9,330 shares0Common StockSEC:0001410442-26-000005:0
9,330 shares0Common StockSEC:0001886518-26-000007:0
1,412 shares@ US$29.5926.5% of flowCommon StockSEC:0002045846-26-000004:0
182 shares@ US$29.5923.8% of flowCommon StockSEC:0002045818-26-000002:0
2,177 shares@ US$29.5927.7% of flowCommon StockSEC:0002012361-26-000004:0
4,964 shares@ US$29.5951.6% of flowCommon StockSEC:0001993528-26-000003:0
2,976 shares@ US$29.594.6% of flowCommon StockSEC:0001788632-26-000006:0
3,368 shares@ US$29.5910.9% of flowCommon StockSEC:0001755882-26-000004:0
11,840 shares@ US$29.599.9% of flowCommon StockSEC:0001626337-26-000004:0
2,045 shares@ US$29.599.2% of flowCommon StockSEC:0001610493-26-000004:0
4,041 shares@ US$19.044.0% of flowCommon StockSEC:0001788632-26-000004:0
54,097 shares@ US$20.3535.1% of flowCommon StockSEC:0001626337-25-000003:0
25 of 175 declarations
关于 Envista Holdings Corp
Envista Holdings Corp. (NYSE: NVST) 是一家在美国纽约证券交易所上市的公司，专注于牙科技术和耗材。该公司通过广泛的产品组合为牙医、正畸医生、实验室和牙科诊所提供服务，旨在诊断、治疗和预防口腔疾病，同时改善笑容美观度。其定位是作为一家全球牙科护理平台，拥有多元化的品牌组合和在超过130个国家的商业覆盖。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)） Envista 于2018年作为 Danaher 的全资子公司成立，并于2019年通过首次公开募股分拆。这一传承很重要，因为公司继续使用 Envista 业务系统 (EBS) 作为核心运营框架，反映了严谨的持续改进文化。其总部位于美国加利福尼亚州布雷亚。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)） 该业务分为两个主要部门。专业产品与技术部门包括牙科种植系统、再生解决方案、牙科修复体、相关治疗软件和技术，以及正畸托槽系统、隐形矫治器和实验室产品。设备与耗材部门涵盖诊断解决方案、牙科设备、耗材和相关服务。对于投资者而言，这种组合很重要，因为它将经常性耗材收入与更多技术主导的差异化产品结合在一起。2024年，约85%的销售额来自耗材、服务和备件，这支持了相对稳定的收入状况。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)） 从竞争角度来看，Envista 是全球最大的牙科产品公司之一。其优势包括产品组合的广度、强大的国际分销能力以及服务多种临床应用的能力，从基于种植体的牙齿替换到正畸、影像和耗材。公司重点介绍了 Nobel Biocare、Ormco、DEXIS 和 Kerr 等品牌，这些品牌在专业牙科渠道中提供了市场认可度和覆盖范围。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1757073/000175707325000022/nvst_2024annualreportx42425.pdf?utm_source=openai)） 最近的发展表明执行力正在改善。在其2025年业绩中，Envista 报告了核心收入的积极增长、利润率的提高、研发投资的增加以及其隐形矫治器业务 Spark 的进展，该业务在2025年下半年实现了正运营利润率。公司还指出管理费用降低并持续进行股票回购。对于法语投资者而言，关键的投资案例是一家具有全球影响力、强大经常性收入基础且运营转型似乎正在取得进展的专业医疗保健公司。（[investors.envistaco.com](https://investors.envistaco.com/2026-02-05-Envista-Reports-Fourth-Quarter-2025-Results?utm_source=openai)）
